November 27, 2012

Isis Pharmaceuticals: Antisense Value

by John McCamant, editor The Medical Technology Stock Letter

Isis Pharmaceuticals (ISIS) has had a lots of news. The first was the announcement that the company will receive $1.1 million from Alnylam as its portion of the upfront fees from a collaboration with Genzyme.

The company also announced that they will receive a $1.25 million contingent payment from Pfizer triggered by Pfizer’s decision to advance EXC 001 into a Phase II trial. Pfizer’s commitment to advancing EXC 001 is a testament to ISIS’ business strategy investment.

The market opportunity to treat hypertrophic scars is very large and Pfizer has the drug development expertise and global commercial infrastructure to support the continued advancement of EXC 001, which ISIS could not do on their own.